Aesthetic medicine of the new generation

M1 Akademie

In-house training and development is a key element of the M1 Group's business model. That is why M1 operates the M1 Akademie. The main topics of the training courses provided are new treatment procedures, innovations and product presentations in the fields of aesthetic medicine as well as plastic and aesthetic surgery. Due to this uniform training and further education of all doctors and medical staff, M1 is able to offer customers the highest quality regardless of location.

M1 Akademie at a glance:

  • Worldwide private training centre for physicians, specialists and dentists
  • Neueste Behandlungsverfahren, Innovationen und
  • Latest treatment procedures, innovations and product presentations for the areas:
    • Aesthetic medicine
    • Plastic and aesthetic surgery
  • Providing practical experience, different techniques and detailed complication management
  • Brain pool with many years of know-how
  • Represented in Germany, Austria, Switzerland, the Netherlands, UK, Croatia, Hungary and Australia

We provide quality, techniques and expertise to doctors

More about M1 Akademie

Latest news

  • Group revenue: +9.5% to EUR 92.7 million (Q1 2024: EUR 84.7 million)
  • EBITDA: +22% to EUR 10.0 million (Q1 2024: EUR 8.2 million)
  • EBIT: +29% to EUR 8.8 million (Q1 2024: EUR 6.8 million)
  • EBIT margin: 9.5% (Q1 2024: 8.1%)
  • EBT: +23% to EUR 8.6 million (Q1 2024: EUR 7.0 million)
  • Earnings per share: EUR 0.31 (Q1 2024: EUR 0.26)

| Investor News

  • Group revenue increased by 7% to EUR 339.2 million (previous year: EUR 316.3 million)
  • EBITDA rose by 52% to EUR 32.0 million (previous year: EUR 21.0 million)
  • EBIT grew by 70% to EUR 26.8 million (previous year: EUR 15.7 million)
  • EBT increased by 60% to EUR 26.3 million (previous year: EUR 16.4 million)
  • Beauty segment revenue rose by 30% to EUR 91.7 million (previous year: EUR 70.8 million)
  • Equity ratio improved from 67% to 71%

| Investor News

  • Group revenue: increase by 7% to EUR 339.2 million (previous year: EUR 316.3 million)
  • EBITDA: increase by 52% to EUR 32.0 million (previous year: EUR 21.0 million)
  • EBIT: increase by 70% to EUR 26.8 million (previous year: EUR 15.7 million)
  • EBT: increase by 60% to EUR 26.3 million (previous year: EUR 16.4 million)
  • Earnings per share: increase of 57% to EUR 0.85 (previous year: EUR 0.54)
  • Equity ratio: increase from 67% to 71%

| Ad-hoc news

HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are currently carefully reviewing the offer.

A possible sale of the trade segment would pave the way for a clear strategic focus of M1 Kliniken AG on the fast-growing beauty business.

The company will provide further information in due course.